Paper: Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Marc S. Raab, M.D. 1 *, Niels Weinhold, PhD 2 *, K. Martin Kortüm, MD 3 *, Jan Krönke, MD 4,5, Lilli Podola 6 *, Uta Bertsch, MD 6 *, Jan H. Frenking, MD 2 *, Julia Mersi, MD 7 *,

Read the full article here

Source: ash.confex.com

Categories: Hem/Oncs, General Medicine News

Tweets with this article

Saad Z. Usmani MD MBA FACP (he/his/him)

- 493 Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial https://t.co/5MtpL2UkzX - 494 Phase 3 Study of Teclistamab (Tec) in Combination… https://t.co/wARGeRry8W

Long Covid Defined | NEJM

Members of the National Academies of Sciences, Engineering, and Medicine describe the process and rationale for the development of the 2024 definition of persistent Covid-19…

Ash Paul November 7, 2024

More suggestions for FDA reform for a Trump presidency

Jessica Adams was a reporter who chosely followed the FDA, here are her suggestions for reform at the US Food and Drug Administration.

Vinay Prasad November 7, 2024

What a Trump presidency can mean for health care

9 suggestions to make America healthy again

Vinay Prasad November 7, 2024

Paper: Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Program: Oral and Poster Abstracts Type: Oral Session: 636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS…

Mike Thompson, MD, PhD, FASCO November 7, 2024

What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs

The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study,…

Bishal Gyawali November 7, 2024

Paper: CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI

Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical…

Saad Z. Usmani MD MBA FACP (he/his/him) November 7, 2024

Related Articles